← Back to Search

Other

[14C]-DZD9008 for Healthy Subjects

Phase 1
Waitlist Available
Led By Blanchard
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug called DZD9008 with a small amount of radioactivity to see how it moves through the body. Healthy male subjects take the drug, and researchers analyze their blood, urine, and feces to understand how the drug is processed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [14C]-DZD9008Experimental Treatment1 Intervention
A Single dose of \[14C\]-DZD9008
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[14C]-DZD9008
2021
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Dizal PharmaceuticalsLead Sponsor
24 Previous Clinical Trials
2,866 Total Patients Enrolled
BlanchardPrincipal InvestigatorCovance
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top